Blogs
Alexza Financing Will Help Near-Term Milestones and Product Launch -- Seeking Alpha
<strong><a href='http://seekingalpha.com/author/sheff-station'>Sheff Station</a>submits:</strong><p>Alexza Pharma (<a href='http://seekingalpha.com/symbol/alxa' alt='Alexza Pharmaceutica' title='Alexza Pharmaceutica'>ALXA</a>) is anxiously awaiting a date with the FDA for a pre-approval inspection
New Challenges to Teva’s Business Model -- Seeking Alpha
<strong><a href='http://israelfinancialexpert.blogspot.com/'>Israel's Financial Expert</a>submits:</strong><div>Teva’s shares fell sharply on Friday after a generic version of Sanofi-Aventis (<a href='http://seekingalpha.com/symbol/sny' alt='Sanofi-Aventis' title='Sanofi-Aventis'>SNY</a>)
Despite Uncertainty, Genzyme Expands Its Manufacturing Base -- Seeking Alpha
<strong><a href='http://www.burrillreport.com/'>The Burrill Report</a>submits:</strong><p><em>By Michael Fitzhugh</em></p><p>Genzyme (<a href='http://seekingalpha.com/symbol/genz' alt='Genzyme Corp.' title='Genzyme Corp.'>GENZ</a>) says it will double the size of its newest Massachusetts
NeoStem Taps Chinese Healthcare Reform Profits -- Seeking Alpha
<strong><a href='http://biomedreports.com/'>M.E. Garza</a>submits:</strong><p>Many of today's investors, I'd venture to say a vast majority of them, don't take the time to read through the public filings of some of their favorite companies. As such, they often fall prey to misinformation or rumors
AstraZeneca's Latest Cost-Cutting Move: Offshore Production -- Seeking Alpha
<img src='http://seekingalpha.com/wp-content/seekingalpha/images/ChinaBioTodaysharplogo.jpg' title='chinabiotodaynewlogo' alt='chinabiotodaynewlogo' width="100" height="30" border='1' align="left" hspace="6" vspace="6" /><strong><a href="http://chinabiotoday.com/">ChinaBio
Sell Genzyme Near Term Due to Continued Manufacturing Challenges -- Seeking Alpha
<p>Yesterday, Genzyme (<a href='http://seekingalpha.com/symbol/genz' title='More opinion and analysis of GENZ'>GENZ</a>) provided a manufacturing update with regard to the production of its blockbuster drug Cerezyme, and Fabrazyme - treatments for Gaucher disease and Fabry disease, respectively.
Short Interest in BioDelivery Sciences Is Good News -- Seeking Alpha
<strong><a href='http://vfcsstockhouse.blogspot.com/'>VFC</a>submits:</strong><p>A comment from a reader:<br><br><em><img src="http://static.seekingalpha.com/uploads/2009/9/2/saupload_bdsi.png" align="right" hspace="6" vspace="6" />I am considering your pick of<span>BioDelivery
Page:
